Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Variable performance of commercial epidermal growth factor receptor antibodies in detection of basal-like breast cancer.

Won JR, Gao D, Grant D, Cupples J, Rahemtulla A, Wolber R, Nielsen TO, Gilks CB.

Histopathology. 2012 Sep;61(3):518-9. doi: 10.1111/j.1365-2559.2012.04262.x. No abstract available.

PMID:
22642766
2.

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.

PMID:
19390427
3.

Analytic variability in immunohistochemistry biomarker studies.

Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL.

Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):982-91. doi: 10.1158/1055-9965.EPI-10-0097.

4.

Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.

Dihge L, Bendahl PO, Grabau D, Isola J, Lövgren K, Rydén L, Fernö M.

Breast Cancer Res Treat. 2008 May;109(2):255-62.

PMID:
17636398
5.

Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.

Hameed O, Chhieng D, Adams AL.

J Clin Oncol. 2008 Mar 20;26(9):1571. doi: 10.1200/JCO.2008.16.6868. No abstract available.

PMID:
18349417
6.

Comparison of radioligand assay and immunostaining for epidermal growth factor receptor in human breast cancer.

Hastrich DJ, Dunn JM, Nicholson S, Newcomb P, Farndon JR.

Br J Surg. 1994 Jun;81(6):853-5.

PMID:
8044601
7.

Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer.

Horiguchi J, Iino Y, Takei H, Yokoe T, Ishida T, Morishita Y.

Oncology. 1994 Jan-Feb;51(1):47-51.

PMID:
7903441
9.

Clinical significance of basal-like subtype in triple-negative breast cancer.

Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H.

Breast Cancer. 2009;16(4):260-7. doi: 10.1007/s12282-009-0150-8.

PMID:
19701681
10.

Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, et al.

Cancer Res. 1993 Oct 15;53(20):4960-70.

11.

Salivary markers: their role in breast cancer detection.

Chase WR.

J Mich Dent Assoc. 2000 Feb;82(2):12. No abstract available.

PMID:
11323899
12.

Progesterone receptor and human epidermal growth factor receptor 2 status: an independent influence on the efficacy of endocrine therapy in breast cancer?

Ponzone R, Maggiorotto F, Robba C, Fuso L, Sismondi P.

J Clin Oncol. 2006 Mar 20;24(9):1481-2; author reply 1482. No abstract available.

PMID:
16549847
13.

Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.

Arnes JB, Bégin LR, Stefansson I, Brunet JS, Nielsen TO, Foulkes WD, Akslen LA.

J Clin Pathol. 2009 Feb;62(2):139-46. doi: 10.1136/jcp.2008.056291.

PMID:
18682421
14.
15.

[Immunohistochemical characteristics of triple negative/basal-like breast cancer].

Pala EE, Bayol Ü, Cumurcu S, Keskın E.

Turk Patoloji Derg. 2012;28(3):238-44. doi: 10.5146/tjpath.2012.01130. Turkish.

16.

Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?

Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM.

Clin Cancer Res. 2005 Jul 1;11(13):4835-42.

17.

Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.

Göhring UJ, Ahr A, Scharl A, Weisner V, Neuhaus W, Crombach G, Holt JA.

J Soc Gynecol Investig. 1995 Jul-Aug;2(4):653-9.

PMID:
9420872
18.

neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues.

Tsutsumi Y, Naber SP, DeLellis RA, Wolfe HJ, Marks PJ, McKenzie SJ, Yin S.

Hum Pathol. 1990 Jul;21(7):750-8.

PMID:
1972932
19.

Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.

González LO, Corte MD, Junquera S, González-Fernández R, del Casar JM, García C, Andicoechea A, Vázquez J, Pérez-Fernández R, Vizoso FJ.

Hum Pathol. 2009 Sep;40(9):1224-33. doi: 10.1016/j.humpath.2008.12.022.

PMID:
19439346
20.

Supplemental Content

Support Center